NASDAQ
IRWD

Ironwood Pharmaceuticals Inc

Drug Manufacturers-Specialty & Generic
Healthcare

Prices are adjusted according to historical splits.

Ironwood Pharmaceuticals Inc Stock Price

Vitals

Today's Low:
$8.17
Today's High:
$8.69
Open Price:
$8.17
52W Low:
$8.07
52W High:
$12.66
Prev. Close:
$8.26
Volume:
3006571

Company Statistics

Market Cap.:
$1.30 billion
Book Value:
-2.216
Revenue TTM:
$427.28 million
Operating Margin TTM:
59.2%
Gross Profit TTM:
$366.33 million
Profit Margin:
-214.68%
Return on Assets TTM:
20.03%
Return on Equity TTM:
-1015.1%

Company Profile

Ironwood Pharmaceuticals Inc had its IPO on 2010-02-03 under the ticker symbol IRWD.

The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Ironwood Pharmaceuticals Inc has a staff strength of 219 employees.

Stock update

Shares of Ironwood Pharmaceuticals Inc opened at $8.17 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $8.17 - $8.69, and closed at $8.66.

This is a +4.84% increase from the previous day's closing price.

A total volume of 3,006,571 shares were traded at the close of the day’s session.

In the last one week, shares of Ironwood Pharmaceuticals Inc have slipped by -6.48%.

Ironwood Pharmaceuticals Inc's Key Ratios

Ironwood Pharmaceuticals Inc has a market cap of $1.30 billion, indicating a price to book ratio of 3.2181 and a price to sales ratio of 4.3955.

In the last 12-months Ironwood Pharmaceuticals Inc’s revenue was $427.28 million with a gross profit of $366.33 million and an EBITDA of $254.21 million. The EBITDA ratio measures Ironwood Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Ironwood Pharmaceuticals Inc’s operating margin was 59.2% while its return on assets stood at 20.03% with a return of equity of -1015.1%.

In Q2, Ironwood Pharmaceuticals Inc’s quarterly earnings growth was a positive 19.1% while revenue growth was a positive 10.4%.

Ironwood Pharmaceuticals Inc’s PE and PEG Ratio

Forward PE
12.3305
Trailing PE
0
PEG
-0.26

Its diluted EPS in the last 12-months stands at $-5.77 per share while it has a forward price to earnings multiple of 12.3305 and a PEG multiple of -0.26. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Ironwood Pharmaceuticals Inc’s profitability.

Ironwood Pharmaceuticals Inc stock is trading at a EV to sales ratio of 4.1469 and a EV to EBITDA ratio of 7.2165. Its price to sales ratio in the trailing 12-months stood at 4.3955.

Ironwood Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$603.22 million
Total Liabilities
$305.39 million
Operating Cash Flow
$-999492000.00
Capital Expenditure
$0
Dividend Payout Ratio
0%

Ironwood Pharmaceuticals Inc ended 2024 with $603.22 million in total assets and $0 in total liabilities. Its intangible assets were valued at $603.22 million while shareholder equity stood at $-346777000.00.

Ironwood Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $305.39 million in other current liabilities, 156000.00 in common stock, $-1712849000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $175.32 million and cash and short-term investments were $175.32 million. The company’s total short-term debt was $202,178,000 while long-term debt stood at $597.97 million.

Ironwood Pharmaceuticals Inc’s total current assets stands at $317.60 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $118.99 million compared to accounts payable of $3.51 million and inventory worth $788000.00.

In 2024, Ironwood Pharmaceuticals Inc's operating cash flow was $-999492000.00 while its capital expenditure stood at $0.

Comparatively, Ironwood Pharmaceuticals Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$8.66
52-Week High
$12.66
52-Week Low
$8.07
Analyst Target Price
$14.5

Ironwood Pharmaceuticals Inc stock is currently trading at $8.66 per share. It touched a 52-week high of $12.66 and a 52-week low of $12.66. Analysts tracking the stock have a 12-month average target price of $14.5.

Its 50-day moving average was $9.97 and 200-day moving average was $10.87 The short ratio stood at 7.74 indicating a short percent outstanding of 0%.

Around 162% of the company’s stock are held by insiders while 10526% are held by institutions.

Frequently Asked Questions About Ironwood Pharmaceuticals Inc

The stock symbol (also called stock or share ticker) of Ironwood Pharmaceuticals Inc is IRWD

The IPO of Ironwood Pharmaceuticals Inc took place on 2010-02-03

Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)

Last Price
Chg
Chg%
$0.87
0.01
+1.6%
$278.4
-15.5
-5.27%
RPC Inc (RES)
$8.44
0.08
+0.96%
$2.87
-0.12
-4.01%
$160.25
-4.9
-2.97%
MIRC ELECTRONICS LTD. (MIRCELECTR)
$25.08
-0.51
-1.99%
$17.18
0.32
+1.9%
$5.75
0.07
+1.23%
$17.03
0.33
+1.98%
$30.11
-0.27
-0.89%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Address

100 Summer Street, Boston, MA, United States, 02110